Search

I4MDS consortium: advancing MDS treatment and understanding

The role of the immune system in the pathophysiology of Myelodysplastic Neoplasms (MDS) is firmly established. However, routine immune monitoring for these patients is still not a common practice.

Read more

Selected EMA news

Most of EHA’s regulatory activities focus on collaboration with the European Medicines Agency (EMA).

Read more

Highlights from the SWG

SWG AML Annual Scientific MeetingThe most recent SWG AML Annual Scientific Meeting took place during the annual EHA Congress in Frankfurt, Germany.

Read more

A new targeted combination therapy with potential to eliminate relapsed chronic lymphocytic leukemia

Patients with chronic lymphocytic leukemia (CLL) that has recurred or isn’t responding to standard treatment need new therapies. A new combination of two targeted therapies is showing potential to eliminate CLL in these circumstances.

Read more

Meeting Program

All times are in GMT-3, local time in Brazil.

Read more

Join EHA and SIE and receive up to €50 discount on your EHA membership

We are pleased to inform you that EHA and the Società Italiana di Ematologia (SIE) have joined forces and are offering you the possibility of an EHA-SIE Joint Membership.

Read more

Treatment of acute lymphoblastic leukemia by activation of patient's immune cells by a bispecific antibody.

 

Abstract S722
Acute lymphoblastic leukemia  (ALL) is a rare type of blood cancer which is mainly treated by intensive chemotherapy.

Read more